Approved comparison material connected to this topic.
7 total recordsSource comparisons are presented without a generated winner.
Raun et al. (1998) Rat pituitary cells 10–300 nM 8-fold vs baseline No change Confirmed GHS-R1a selectivity; no ACTH pathway activation at any concentration tested Johansen et al. (1999) Swine 0.1–1.0 mg/kg 12…
Ipamorelin GHS-R1a (selective) Pulsatile, physiological amplitude None Isolated GH studies, metabolic research, bone density trials GHRP-6 GHS-R1a + hypothalamic ghrelin receptors Pulsatile, moderate amplitude…
IGF-1 LR3 vs Ipamorelin — Mechanism, Dosing, Applications IGF-1 LR3 directly binds IGF receptors promoting tissue growth; Ipamorelin stimulates endogenous GH release for gradual anabolic effects. Research publ…
IGF-1 LR3 bypasses the GH-IGF-1 axis entirely. Native IGF-1 binds tightly to six IGF-binding proteins (IGFBPs) in serum, which sequester the hormone and limit tissue availability. The R3 modification. Substitu…
Research published in the Journal of Clinical Endocrinology & Metabolism found that IGF-1 LR3 (insulin-like growth factor-1 long R3) produces tissue-level anabolic effects independent of growth hormone (GH) se…
Primary Mechanism Direct IGF-1 receptor agonist; bypasses GH pathway entirely GHSR1a agonist; stimulates endogenous GH release from pituitary IGF-1 LR3 produces immediate tissue effects; Ipamorelin requires fu…
Here's the honest answer: most researchers misunderstand what they're comparing when they evaluate IGF-1 LR3 and Ipamorelin. These aren't two versions of the same compound with slightly different potency. They…